Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Casopitant for Prevention of CINV in Cisplatin-Based Chemotherapy
NCT00431236Phase 3Completed
- Sponsor
- GSK
- Start
- Nov 2006
- Primary completion
- Oct 2007
- Modality
- Small Molecules
- Countries
- 22
01
Overview
Phase 3, randomised, double-blind trial of casopitant in chemotherapy-induced nausea and vomiting (CINV) (3 arms), sponsored by GSK. Primary endpoint: Number of participants who achieved complete response. Started Nov 2006; status: completed.
02
Drugs
casopitant
03
Conditions
chemotherapy-induced nausea and vomiting (CINV)
Beyond the preview
Go deeper on NCT00431236.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT00431236.